Stifel Maintains Buy on Summit Therapeutics, Lowers Price Target to $38

Benzinga Newsdesk www.benzinga.com Negative 68.5%

Neg 68.5% Neu 0% Pos 0%

Stifel analyst Dara Azar maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $45 to $38.